Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells

Dmitry Polikarpov, Liuen Liang, Andrew Care, Anwar Sunna, Douglas Campbell, Bradley Walsh, Irina Balalaeva, Andrei Zvyagin, David Gillatt, Evgenii Guryev

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.
LanguageEnglish
Article number820
Pages1-11
Number of pages11
JournalBiomolecules
Volume9
Issue number12
DOIs
Publication statusPublished - 3 Dec 2019

Fingerprint

Glypicans
Urinary Bladder Neoplasms
Nanoparticles
Labeling
Cells
Silicon Dioxide
Nanoconjugates
Antibodies
Tumors
Carcinoma
Neoplasms
Cystoscopy
Biopsy
Fluorescence
Infrared radiation
Technology
Light
Recurrence
Peptides

Bibliographical note

Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • upconversion nanoparticles
  • photoluminescent nanocomplexes
  • bladder cancer
  • solid-binding peptide
  • glypican-1
  • photodynamic diagnostics

Cite this

@article{0eb54a8b0d2848f29126a1b8cd369b91,
title = "Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells",
abstract = "Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.",
keywords = "upconversion nanoparticles, photoluminescent nanocomplexes, bladder cancer, solid-binding peptide, glypican-1, photodynamic diagnostics",
author = "Dmitry Polikarpov and Liuen Liang and Andrew Care and Anwar Sunna and Douglas Campbell and Bradley Walsh and Irina Balalaeva and Andrei Zvyagin and David Gillatt and Evgenii Guryev",
note = "Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2019",
month = "12",
day = "3",
doi = "10.3390/biom9120820",
language = "English",
volume = "9",
pages = "1--11",
journal = "Biomolecules",
issn = "2218-273X",
publisher = "MDPI",
number = "12",

}

Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells. / Polikarpov, Dmitry; Liang, Liuen; Care, Andrew; Sunna, Anwar; Campbell, Douglas; Walsh, Bradley; Balalaeva, Irina; Zvyagin, Andrei; Gillatt, David; Guryev, Evgenii.

In: Biomolecules, Vol. 9, No. 12, 820, 03.12.2019, p. 1-11.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells

AU - Polikarpov, Dmitry

AU - Liang, Liuen

AU - Care, Andrew

AU - Sunna, Anwar

AU - Campbell, Douglas

AU - Walsh, Bradley

AU - Balalaeva, Irina

AU - Zvyagin, Andrei

AU - Gillatt, David

AU - Guryev, Evgenii

N1 - Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2019/12/3

Y1 - 2019/12/3

N2 - Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.

AB - Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.

KW - upconversion nanoparticles

KW - photoluminescent nanocomplexes

KW - bladder cancer

KW - solid-binding peptide

KW - glypican-1

KW - photodynamic diagnostics

UR - http://www.scopus.com/inward/record.url?scp=85076266854&partnerID=8YFLogxK

U2 - 10.3390/biom9120820

DO - 10.3390/biom9120820

M3 - Article

VL - 9

SP - 1

EP - 11

JO - Biomolecules

T2 - Biomolecules

JF - Biomolecules

SN - 2218-273X

IS - 12

M1 - 820

ER -